ReviewClinical ophthalmology (Auckland, N.Z.)2026
Clinical Outcomes of the First Diffractive Trifocal Intraocular Lens: A Literature Review.
Review in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this review article is to summarise the clinical outcomes reported in patients implanted with FineVision diffractive trifocal intraocular lenses (IOLs). Methods: We searched the PubMed (US National Library of Medicine) and Scopus (Elsevier) databases on 18 October 2025. We included any type of prospective or retrospective study published in a peer-reviewed journal reporting the clinical outcomes of patients who were implanted with the FineVision Micro F, FineVision POD/POD FT or the FineVision HP (POD F GF/POD FT 49P) IOL models after cataract or refractive lens exchange surgeries. Results: A total of 97 clinical studies published between 2012 and 2025 were obtained, and, of these, the three with the maximum number of eyes recruited and the longest follow-up per IOL model were included in this review. The most important data in these 9 publications was analysed, considering refractive accuracy, rotation stability, visual acuity at different distances (far, intermediate and near), defocus curves, photopic and mesopic contrast sensitivity, patient-reported outcome questionnaires, ocular aberrations, light distortion, photic phenomena and adverse events. Conclusion: The outcomes analyzed in the present review lead us to conclude that FineVision diffractive trifocal IOLs provide good clinical performance when implanted. The most up-to-date FineVision HP model, hydrophobic with a double C-loop, provides excellent refractive accuracy, good visual performance, and patient satisfaction with high spectacle independence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.